| Compound | Cagrilintide |
|---|---|
| Category | Long-acting amylin analog |
| Class | GLP-1 and Incretin Therapies |
| Evidence tier | Clinical-stage |
| WADA status | Not individually listed; verify current status if subject to testing |
| Sold on this site | No — this is a reference database |
Overview
Cagrilintide — a long-acting amylin analog — sits in the "Clinical-stage" tier of this catalog. This compound has completed or is undergoing formal human trials. Human safety and efficacy are being characterized, but no universal approval exists and results may still fail or be withdrawn.
A long-acting amylin analog under investigation for obesity, both as monotherapy and in fixed combination with semaglutide (CagriSema). Amylin is a satiety hormone co-secreted with insulin by pancreatic beta cells.
Mechanism of Action
Cagrilintide activates amylin receptors, which modulate satiety, gastric emptying, and glucagon secretion. Its fatty-acid side chain extends the half-life to about a week, enabling once-weekly dosing and combination with weekly GLP-1 therapy.
Research and Evidence
A phase 2 monotherapy trial reported roughly 10% mean weight reduction over 26 weeks at the highest dose, and phase 3 trials of the CagriSema combination have reported weight reductions above 20% in obesity.
Safety and Side Effects
Reported adverse effects have centered on gastrointestinal symptoms; long-term safety data and final labeled warnings are pending completion of the registrational program.
Frequently Asked Questions
What is the evidence tier of Cagrilintide?
Cagrilintide is graded "Clinical-stage" on this site. This compound has completed or is undergoing formal human trials. Human safety and efficacy are being characterized, but no universal approval exists and results may still fail or be withdrawn.
Is Cagrilintide an approved medicine?
No. Clinical-stage means the compound has not reached universal regulatory approval; the tier description above explains exactly what level of evidence exists.
Where can I read the primary studies for Cagrilintide?
The references section at the end of this entry links the key primary sources — regulator labels, trial registrations, and peer-reviewed papers. Our "How to Read a Peptide Study" guide explains how to evaluate them.
References
- ClinicalTrials.gov — registered cagrilintide studies. [source]
Evidence tier: Clinical-stage · Last reviewed: 2026-09-05 · Sources cited below.